Pfizer Ltd. Technical Momentum Shifts to Bearish Amid Market Pressure

Technical Trend Overview

Recent analysis reveals that Pfizer Ltd.'s technical trend has shifted from mildly bearish to outright bearish, reflecting a growing negative sentiment among traders and investors. The daily moving averages have turned bearish, indicating that the stock's short-term price action is under pressure. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, suggesting that momentum is weakening across multiple timeframes.

Bollinger Bands reinforce this bearish outlook, with both weekly and monthly signals indicating downward pressure. The stock’s price has been hovering near the lower band, a sign of increased volatility and potential continuation of the downtrend. Meanwhile, the weekly KST (Know Sure Thing) indicator shows a mildly bullish signal, but this is offset by the monthly KST’s mildly bearish stance, highlighting mixed momentum signals that lean towards caution.

Price and Volume Dynamics

Pfizer Ltd. closed at ₹4,647.45, down 1.01% from the previous close of ₹4,694.65. The intraday range was between ₹4,626.30 and ₹4,698.00, with the stock failing to breach the 52-week high of ₹5,987.65. The 52-week low stands at ₹4,461.80, indicating that the current price is closer to the lower end of its annual range, which may be a concern for investors seeking stability.

On the volume front, the On-Balance Volume (OBV) indicator shows no clear trend on a weekly basis and a mildly bearish trend monthly. This suggests that volume is not strongly supporting any upward price movement, which is a negative sign for potential buyers. The lack of volume confirmation often precedes further price declines or sideways consolidation.

Relative Strength Index (RSI) and Momentum Signals

The RSI readings for Pfizer Ltd. are neutral, with no significant signals on either the weekly or monthly charts. This absence of momentum extremes indicates that the stock is neither overbought nor oversold, leaving room for further downside or sideways movement. Investors should monitor RSI closely for any divergence or movement into oversold territory, which could signal a potential reversal or buying opportunity.

Comparative Performance Against Sensex

When compared to the broader market benchmark, the Sensex, Pfizer Ltd. has underperformed over most recent periods. Over the past week, the stock declined by 2.74%, while the Sensex gained 1.08%. Over one month, Pfizer fell 1.84% compared to the Sensex’s 0.85% loss. Year-to-date, Pfizer’s return stands at -6.72%, outperforming the Sensex’s steeper decline of -10.81%. However, over the one-year horizon, Pfizer’s return of -10.09% lags behind the Sensex’s -7.50%.

Longer-term performance shows mixed results. Over three years, Pfizer has delivered a 22.12% return, slightly ahead of the Sensex’s 21.61%. Yet, over five years, Pfizer’s return of -11.75% significantly trails the Sensex’s robust 48.99% gain. Over a decade, Pfizer has posted a strong 153.58% return, though still below the Sensex’s 188.28% growth, reflecting the challenges faced by the company in recent years.

Mojo Score and Rating Update

MarketsMOJO has downgraded Pfizer Ltd.’s rating from Hold to Sell as of 29 Dec 2025, reflecting the deteriorating technical and fundamental outlook. The current Mojo Score stands at 37.0, which is relatively low and indicative of weak momentum and limited upside potential. The small-cap market capitalisation further adds to the stock’s risk profile, as liquidity and volatility concerns remain pertinent.

The downgrade aligns with the technical indicators signalling bearish momentum and the stock’s underperformance relative to the broader market. Investors should exercise caution and consider the implications of this rating change in their portfolio allocation decisions.

Moving Averages and Dow Theory Signals

Daily moving averages have turned bearish, with the stock trading below key averages, signalling a negative short-term trend. The Dow Theory analysis presents a mixed picture: no clear trend on the weekly timeframe but a mildly bullish signal on the monthly chart. This divergence suggests that while short-term momentum is weak, there may be some underlying longer-term support, though this is not yet strong enough to reverse the bearish technical stance.

Outlook and Investor Considerations

Given the current technical landscape, Pfizer Ltd. faces headwinds in regaining upward momentum. The bearish MACD and Bollinger Bands, combined with weak volume support and neutral RSI, point to a cautious near-term outlook. The stock’s proximity to its 52-week low and underperformance relative to the Sensex add to the risk factors.

Investors should monitor key support levels around ₹4,460 and watch for any positive divergence in momentum indicators that could signal a potential recovery. Until then, the technical signals favour a defensive stance, with a preference for risk management and selective exposure.

Summary

Pfizer Ltd.’s technical parameters have shifted decisively towards a bearish outlook, with multiple indicators confirming weakening price momentum and increased selling pressure. The downgrade to a Sell rating by MarketsMOJO reflects these developments and the stock’s relative underperformance. While some longer-term indicators hint at mild bullishness, the prevailing trend remains negative, urging investors to approach with caution.

Monitoring key technical levels and momentum indicators will be crucial in assessing any potential turnaround. Until then, Pfizer Ltd. remains a challenging proposition within the Pharmaceuticals & Biotechnology sector, especially for those seeking stable or growth-oriented small-cap investments.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today